Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q1 FY25 results · Apr–Jun 2024
Morepen Laboratories reported revenue from operations of ₹455.22 crore (up 13.5% from Q1 FY24) and net profit of ₹36.17 crore (up 147.2% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 455.22 | 401.04 | +13.5% | 423.07 | +7.6% |
| Other income | 3.43 | 2.42 | +41.6% | 4.24 | −19.2% |
| Total income | 458.64 | 403.46 | +13.7% | 427.32 | +7.3% |
| Profit before tax | 48.17 | 20.51 | +134.8% | 42.20 | +14.1% |
| Net profit for the period | 36.17 | 14.63 | +147.2% | 28.28 | +27.9% |
| EPS, basic (₹) | 0.71 | 0.29 | +144.8% | 0.54 | +31.5% |
| Net margin (%) | 7.9 | 3.6 | 6.7 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 385.64 | 369.10 | +4.5% | 392.60 | −1.8% |
| Other income | 3.07 | 2.08 | +47.4% | 3.99 | −22.9% |
| Total income | 388.72 | 371.19 | +4.7% | 396.59 | −2.0% |
| Profit before tax | 47.05 | 21.71 | +116.7% | 52.71 | −10.7% |
| Net profit for the period | 35.05 | 15.85 | +121.1% | 39.96 | −12.3% |
| EPS, basic (₹) | 0.69 | 0.31 | +122.6% | 0.78 | −11.5% |
| Net margin (%) | 9.1 | 4.3 | 10.2 |
Consolidated
- Filed with BSE
- 13 Aug 2024, 15:18 IST
- Board meeting
- 12 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2024, 15:18 IST
- Board meeting
- 12 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE